Status:
COMPLETED
Investigation the Safety and Efficacy of The Antileukotriene Agents, Montelukast, as Adjuvant Therapy in Obese Patients With Type 2 Diabetes Mellitus
Lead Sponsor:
Sadat City University
Conditions:
Obesity; Endocrine; Diabetes Type 2
Eligibility:
All Genders
18-60 years
Phase:
EARLY_PHASE1
Brief Summary
The aim of the current study is to evaluate the safety and efficacy of Montelukast in treatment of obese patients with type 2 diabetes (T2DM).
Eligibility Criteria
Inclusion
- \- type 2 diabetic patients who had body mass index (BMI) ≥ 30 kg/m2 , were treated with metformin alone and had ages ranging from 18 to 60 years.
Exclusion
- patients who had any other inflammatory disease
- patients with cardiovascular,
- patients with asthma
- patients with severe hepatic
- patients with renal disease,
- patients with epilepsy
- pregnant or lactating females.
Key Trial Info
Start Date :
July 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 10 2023
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04075110
Start Date
July 1 2019
End Date
April 10 2023
Last Update
April 11 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Faculty of Medicine
Shebin Elkom, Egypt